title: Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination.
abstract: T-cell costimulation typically occurs in a defined microenvironment that is not recapitulated by agonistic antibody therapy. To deliver such stimulation under more favorable conditions, we investigated whether an allogeneic cell-based vaccine that secreted Fc-OX40L, Fc-ICOSL, or Fc-4-1BBL would activate and expand T cells comparably with systemically administered agonist antibodies. Among these costimulators, locally secreted Fc-OX40L provided superior priming of antigen-specific CD8(+) T cells, compared with combinations with OX40 antibodies or vaccine alone. Vaccine-expressed Fc-OX40L also stimulated IFNγ, TNFα, granzyme B, and IL2 by antigen-specific CD8(+) T cells similarly to OX40 antibodies, without off-target consequences such as proinflammatory cytokine induction. Vaccine-secreted Fc-OX40L increased CD127(+)KLRG-1(-) memory precursor cells during the contraction phase, resulting in improved proliferation upon secondary antigen challenge, as compared with OX40 antibody. A cell-based vaccine cosecreting gp96-Ig and Fc-OX40L led to even more pronounced tumor control, complete tumor rejection, and increased tumor antigen-specific T-cell proliferation, including in tumor-infiltrating lymphocytes, as compared with combinations of gp96-Ig vaccine and OX40 antibodies, in mice with established melanoma or colorectal carcinoma. These data suggest that local modulation of the vaccine microenvironment has unexpected advantages over systemic costimulation with agonistic antibodies, which may simplify the clinical translation of such combination immunotherapies into humans. Cancer Immunol Res; 4(9); 766-78. ©2016 AACR.
authors.affiliation: Heat Biologics, Inc., Durham, North Carolina.
authors.forename: George
authors.initials: G
authors.lastname: Fromm
authors.affiliation: Heat Biologics, Inc., Durham, North Carolina.
authors.forename: Suresh
authors.initials: S
authors.lastname: de Silva
authors.affiliation: Heat Biologics, Inc., Durham, North Carolina.
authors.forename: Louise
authors.initials: L
authors.lastname: Giffin
authors.affiliation: Heat Biologics, Inc., Durham, North Carolina.
authors.forename: Xin
authors.initials: X
authors.lastname: Xu
authors.affiliation: Heat Biologics, Inc., Durham, North Carolina.
authors.forename: Jason
authors.initials: J
authors.lastname: Rose
authors.affiliation: Heat Biologics, Inc., Durham, North Carolina. tschreiber@heatbio.com.
authors.forename: Taylor H
authors.initials: TH
authors.lastname: Schreiber
mesh_terms: D053330:4-1BB Ligand / Q000037:antagonists & inhibitors / Q000276:immunology; D019264:Adoptive Transfer; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology; D023201:CD40 Ligand / Q000037:antagonists & inhibitors / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D019496:Cancer Vaccines / Q000276:immunology*; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D007109:Immunity; D007156:Immunologic Memory; D008546:Melanoma, Experimental; D008562:Membrane Glycoproteins; D051379:Mice; D009369:Neoplasms / Q000276:immunology* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D013601:T-Lymphocytes / Q000276:immunology* / Q000378:metabolism
chemical_list: D053330:4-1BB Ligand; D000911:Antibodies, Monoclonal; D019496:Cancer Vaccines; D008562:Membrane Glycoproteins; C053387:endoplasmin; D023201:CD40 Ligand